S&P 500 Healthcare Sector SEC Filings — June 11, 2026

Director Kenneth A. Burdick sold 80,000 shares at $64.55 for ~$5.16M. This is an open-market sale (not under a 10b5-1 plan), which is a high-conviction bearish signal. He still holds 197,086 shares, maintaining significant skin in the game, but the magnitude ($5.16M) suggests potential concern about valuation or fundamentals

EVP Ilya Yuffa sold 2,500 shares at $1,150.77 for ~$2.88M under a Rule 10b5-1 plan. While pre-planned reduces its signaling power, the timing near all-time highs and the large dollar amount merits attention for a top executive

EVP & Pres Med.Essntl&BioPharm Michael David Garrison sold 1,100 shares at $151.48 for ~$167K under a 10b5-1 plan. The relatively small size coupled with the plan structure makes this a low-conviction signal, but it adds to the bearish insider activity pattern in the batch

Chairman & CEO Daniel Patrick O'Day exercised 8,779 RSUs and had 4,213 shares withheld for taxes (~$512K). This is routine tax withholding, not a directional signal. His remaining 622,133 share stake shows strong alignment with shareholders

Seven directors were each awarded 1,505 common stock shares in a coordinated grant. Director Freire Maria C received a larger award of 2,005 shares. This is standard equity compensation with no market-timing signal, but the uniformity suggests a scheduled annual grant

Three directors received Deferred Share Units (DSUs) at $232.79, totaling ~$119K. DSU awards are routine compensation deferrals and carry no trading signal

Director Michael B. McCallister gifted 1,209 common stock. Gifting is often for estate planning or charitable purposes and is not a bearish signal in isolation, but it reduces direct economic exposure

Four senior executives (CMO, CFO, GC, CCO) all had RSU vestings and tax withholdings on the same day at $121.48. The coordinated vesting schedule suggests a company-wide RSU release date, reinforcing the routine nature

Director Burdick's $5.16M open-market sale is a red flag. No 10b5-1 plan means he actively chose to sell at $64.55. With Centene's managed care margins under political pressure from Medicaid redeterminations and pricing scrutiny, this sale could signal impending negative news

EVP Yuffa's $2.88M sale at $1,150.77 comes with Lilly trading near historical highs. While under a 10b5-1 plan, the timing creates optics risk; any guidance miss or pipeline setback could amplify downside given elevated valuation multiples

Despite 11 director filings (all awards), zero open-market purchases were detected. The absence of insider buying when stock is down ~20% from 2024 highs suggests management conviction may be lacking

J&J directors received only deferred units, not open-market purchases. Combined with zero insider buying across the batch, this pattern indicates no urgent bullish conviction among healthcare leadership

The $167K sale at $151.48 comes as BDX faces headwinds from medical device supply-chain normalization and margin compression. While small, it adds to a multi-quarter pattern of insider selling across the medical device subsector

O'Day and Dickinson combined had ~$675K in shares withheld for taxes. Though routine, this concentration of tax-related sales on the same day signals potentially large upcoming tax bills, and if the stock declines, further tax-selling could pressure the stock

Director McCallister's gift of 1,209 shares reduces his stake. Gifts can precede more aggressive selling or signal a desire to reduce exposure without direct market sale. Zoetis has been facing generic competition headwinds

If Burdick's sale is purely diversification (he still holds 197K shares worth ~$12.7M), the market might overreact. Centene trades at ~9x forward earnings vs managed care sector average of ~12x. The sale could create a buying opportunity if Q2 fundamentals (next earnings in July) show margin stabilization

Yuffa's sale under a 10b5-1 plan was likely set months ago. The plan itself suggests the company's trading window was open, and he opted to sell. If you believe in Lilly's GLP-1 pipeline (Mounjaro/Zepbound), the sale is noise and any post-sale dip is a buying opportunity

CEO O'Day holds 622,133 shares worth ~$75.6M. This massive alignment strongly incentivizes long-term value creation. With Gilead's HIV and oncology pipeline producing positive data, the stock at $121.48 offers a 3.9% dividend yield with insider skin in the game

The uniform director awards (1,505 shares each) suggest a stable governance structure and a pre-set compensation calendar. Biogen's Alzheimer's drug Leqembi has a long revenue runway, and the routine awards indicate no internal turmoil

Directors opting for deferred units at $232.79 signals confidence in long-term value. J&J's pharmaceutical (Stelara, Darzalex) and medtech segments provide diversified revenue, and the 3.2% dividend yield with 60+ years of increases is a compounding machine

The 10b5-1 plan means Garrison's sale is mechanical, not opportunistic. BDX's $151.48 price is near 52-week lows, and with its medical device portfolio diversified across medication management, diagnostics, and biopharma, the stock may be oversold

With total tax-related sales of ~$904K across four executives, there is predictable selling pressure. Once these plans reset, the overhang clears, and the stock could rally into earnings. The consistent $121.48 price across all transactions suggests a strong support level

Across all 21 filings, there is not a single open-market purchase by any insider. Zero CEOs or directors voluntarily bought shares. This universal lack of buying suggests that management teams across big pharma, biotech, and healthcare services do not view their stocks as compelling bargains at current levels

Three of the four sell transactions (Eli Lilly, BD, Gilead tax-withholding) were executed under pre-arranged plans. While this reduces signaling power, the aggregate $3.5M+ in planned sales indicates that senior executives are systematically reducing exposure, possibly for portfolio rebalancing or tax planning

Biogen (11 filings) and Gilead (5 filings) account for 76% of the batch. This reflects the high number of directors and executives receiving equity grants at these companies, not necessarily higher conviction activity. Investors should differentiate between compensation events and discretionary trades

14 of the 21 filings are director stock or DSU awards (7 Biogen directors, 3 J&J directors, 1 Zoetis gift). These are mechanical compensation events. The 4 discretionary sales (Centene, Lilly, BD, Zoetis gift) far outweigh the 0 discretionary purchases, painting a cautious picture of insider sentiment

All 21 filings are Form 4 insider trading reports, not 10-K, 10-Q, or 8-K filings. Therefore, no period-over-period comparisons, revenue trends, margin data, or guidance updates are available in this batch. This is a data consideration — forward-looking insights will require future 10-Q/8-K filings

Watch for future Form 4 filings from Director Burdick or other Centene insiders. If his remaining 197K shares are further liquidated, it would amplify the bearish signal. The Q2 2026 earnings call (expected late July) is a key catalyst — watch for managed care margin commentary

Monitor whether Yuffa files additional sales in the coming weeks. A pattern of consecutive sales would suggest a more negative outlook. Also watch for Lilly's ALIGN-2 readout for oral GLP-1 (expected H2 2026) — positive data could justify current valuation

With 7 director awards and 1 option exercise, Biogen insider activity is quiet. However, the Q2 2026 earnings call (late July) will reveal Leqembi launch trajectory. If revenue disappoints, the lack of insider buying could precede more aggressive selling

The coordinated tax-withholding sales hit $904K in total. The next RSU vesting date will create further predictable selling. Monitor if Chairman O'Day files any open-market sales — his 622K-share stake is critical to watch for any reduction

Directors receiving DSUs at $232.79 may later convert. Watch for any DSU conversion filings — especially if the stock appreciates. A large conversion could signal a desire to lock in gains. Also, J&J's talc litigation developments remain a key overhang

With a known 10b5-1 plan, the next trading window after the plan expires will be informative. If Garrison files another sale immediately, it's negative; if he holds, it's stabilizing. BDX earnings in early August will provide margin and guidance updates